Glenn Baity Net Worth

The estimated Net Worth of Glenn Baity is at least $5.91 Millón dollars as of 29 January 2018. Glenn Baity owns over 36,558 units of Acadia Pharmaceuticals Inc stock worth over $1,335,557 and over the last 15 years Glenn sold ACAD stock worth over $4,573,867.

Glenn Baity ACAD stock SEC Form 4 insiders trading

Glenn has made over 25 trades of the Acadia Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Glenn sold 36,558 units of ACAD stock worth $1,184,114 on 29 January 2018.

The largest trade Glenn's ever made was exercising 74,321 units of Acadia Pharmaceuticals Inc stock on 2 January 2018 worth over $162,020. On average, Glenn trades about 17,225 units every 51 days since 2010. As of 29 January 2018 Glenn still owns at least 83,734 units of Acadia Pharmaceuticals Inc stock.

You can see the complete history of Glenn Baity stock trades at the bottom of the page.

What's Glenn Baity's mailing address?

Glenn's mailing address filed with the SEC is 3611 VALLEY CENTRE DRIVE, SUITE 300, , SAN DIEGO, CA, 92130.

Insiders trading at Acadia Pharmaceuticals Inc

Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... y Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.

What does Acadia Pharmaceuticals Inc do?

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies

Complete history of Glenn Baity stock trades at Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc executives and stock owners

Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Stephen Davis,
  Director and Chief Executive Officer
• Srdjan Stankovic,
  President
• Michael Yang,
  Executive Vice President, Chief Commercial Officer
• Elena Ridloff,
  Executive Vice President, Chief Financial Officer
• Austin Kim,
  Executive Vice President, General Counsel, and Secretary
• Stephen R. Davis J.D.,
  CEO & Director
• Dr. Srdjan R. Stankovic,
  Pres
• Austin D. Kim,
  Exec. VP, Gen. Counsel & Sec.
• Daniel Soland,
  Independent Director
• James Daly,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Stephen Biggar,
  Independent Chairman of the Board
• Laura Brege,
  Independent Director
• Julian Baker,
  Independent Director
• Mark Johnson,
  Vice President, Investor Relations
• Elizabeth Garofalo,
  Director
• James Kihara,
  Principal Accounting Officer
• Ponni Subbiah,
  Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
• Mark Schneyer,
  Senior Vice President, Business Development and Chief Business Officer
• Stephanie Fagan,
  Senior Vice President - Corporate Affairs, Chief Communications Officer
• Gudarz Davar,
  Executive Vice President - Head of Research and Development
• Julie Fisher,
  Sr. VP of Marketing & Commercial Strategy
• Dr. Kathie M. Bishop Ph.D.,
  Sr. VP, Chief Scientific Officer & Head of Rare Disease
• Bob Mischler,
  Sr. VP of Strategy & Technology Operations
• James K. Kihara,
  VP, Corp. Controller & Principal Accounting Officer
• Brendan Teehan,
  Exec. VP, COO & Head of Commercial
• Bros. Advisors Lpbaker Feli...,
  
• Mary Ann Gray,
  Director
• Terrence O Moore,
  EVP, CHIEF COMMERCIAL OFFICER
• L.P.667, L.P.Baker Bros. Ad...,
  
• Leslie L Iversen,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lp14159, L.P...,
  
• Todd S. Young,
  EVP AND CFO
• Roger Mills,
  Executive VP, Development
• Uli Hacksell,
  Chief Executive Officer
• Michael T Borer,
  Director
• Thomas H Aasen,
  VP, CFO, Sec. Treas.
• Lester J Ph D Kaplan,
  Director
• Torsten Rasmussen,
  Director
• Robert E Davis,
  Exec. VP, Drug Discovery
• William Mc Dowall Wells,
  
• Bros Advisors Llcbaker Feli...,
  
• Bioscience Partners Iv Lpmr...,
  
• Osch Martien Van,
  Director
• Bioscience Partners Iv Lpob...,
  
• Carl L Gordon,
  Director
• Felixbaker Julianbaker Bros...,
  
• Mark R Brann,
  Pres., Chf. Scientific Officer
• Alan Walton,
  Director
• Glenn Baity,
  EVP AND GC
• Bo Ragnar Tolf,
  VP Chm/Mng Dir ACADIA Phrm A/S
• Gordon M Binder,
  Director
• Brian Lundstrom,
  Sr. VP. Business Development
• John Joseph Kaiser,
  VP, Strat. Mrkting & Com. Dev.
• Adora Ndu,
  
• Brendan Teehan,
  EVP, COO, HEAD OF COMMERCIAL
• Douglas J Williamson,
  Executive VP, Research & Dev
• Bros. Advisors Lp667, L.P.B...,
  
• Jennifer J Rhodes,
  EVP, CHIEF LEGAL OFFICER, SEC
• Elizabeth H.Z. Thompson,
  EVP, Head of Research & Dev